Yann D’Herve joins Cohance Lifesciences as CEO – CDMO Business

New Delhi: Cohance Lifesciences has appointed Yann D’Herve as Chief Executive Officer of the company’s Contract Development and Manufacturing Organization (CDMO) business.

The business operates as a fully integrated, innovation-led platform serving global pharmaceutical companies, including capabilities in small molecule APIs, Antibody Drug Conjugates (ADCs) and Nucleic Acid Chemistry.

Effective August 1, 2025, D’Herve’s appointment brings a strong track record of senior-level leadership to Cohance. He has a rich and diverse background spanning multiple business functions and geographies. His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors.

Most recently, D’Herve served as Senior Vice President and General Manager of Evonik’s Healthcare division, where he was responsible for 2,600 employees across nine manufacturing sites, with full P&L responsibility, including for the company’s CDMO business. Prior to that, he held several senior roles at Evonik including as Vice President of Sales and Services, and divisional leadership assignments. He began his career in manufacturing, gaining hands-on experience in production and operations. Mr. D’Herve holds an MBA from Université de Picardie Jules Verne in Amiens, and a master’s in chemistry from CPE, Lyon, France.

On the appointment of Yann D’Herve, Vivek Sharma, Executive Chairman of Cohance Lifesciences Ltd., commented, “We are delighted to welcome Yann to Cohance. His deep experience in leading multifaceted global pharmaceutical services businesses will be of tremendous benefit in accelerating the growth of our CDMO platform.”

Yann D’Herve, shared: “I am excited to join a growing CDMO with differentiated technologies such as ADCs and oligonucleotides and a strong global asset base. I look forward to working with the Cohance team to support the development and manufacturing of life-saving drugs for our partners.”.